Transitional cell carcinoma MRI

Transitional cell carcinoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Transitional cell carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Cystoscopy and Bladder Biopsy
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Transitional cell carcinoma MRI On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Transitional cell carcinoma MRI All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Transitional cell carcinoma MRI
CDC on Transitional cell carcinoma MRI
Transitional cell carcinoma MRI in the news
Blogs on Transitional cell carcinoma MRI
Directions to Hospitals Treating Transitional cell carcinoma
Risk calculators and risk factors for Transitional cell carcinoma MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

MRI

Transitional cell carcinoma of bladder

• MRI is superior to other modalities in locally staging the tumor and is in some instances able to distinguish T1 from T2 tumors on T2 weighted image.

• T1: isointense compared to muscle
• T2: slightly hyperintense compared to muscle
• T1 weighted image with gadolinium contrast: demonstrates enhancement

Transitional cell carcinoma of the renal pelvis

• Transitional cell carcinomas are isointense to renal parenchyma on both T1 and T2 weighted images. Following administration of Gadolinium, TCCs enhance but less so than normal renal parenchyma.
• T1 : Isointense to renal parenchyma
• Moderate enhancement on gadolinium